Specialist venture capital firm SV Life Sciences has hired a trio of new venture partners for its biotechnology investment team.
Dan Burgess, Ed Mascioli and Michael Mendelsohn will work on investing in innovative medicines, platform technologies and diagnostics addressing significant unmet medical needs.
Burgess was founder, president and CEO of antibiotics business Rempex Pharmaceuticals, Mascioli spent time as CEO of SVLS portfolio company Affinium Pharmaceuticals.
Mendelsohn was formerly senior vice president and global franchise head of cardiovascular diseases at Merck Research Laboratories.
SVLS managing partner Michael Ross said, “We are extremely pleased to have such talented and experienced individuals join the SVLS team.
“These strategic hires position us to expand our sourcing and investment activities within the biotech sector and develop our portfolio dedicated to the space.”
Copyright © 2014 AltAssets